Oral Pharmacologic Treatment of Type 2 Diabetes

2017 ◽  
Vol 166 (4) ◽  
pp. I-18
Keyword(s):  
Type 2 Diabetes ◽  
Pharmacologic Treatment

scholarly journals Optimal Pharmacologic Treatment Strategies in Obesity and Type 2 Diabetes

2014 ◽  
Vol 3 (2) ◽  
pp. 595-613 ◽  
Author(s):  
Gayotri Goswami ◽  
Nataliya Shinkazh ◽  
Nichola Davis
Keyword(s):  
Type 2 Diabetes ◽  
Treatment Strategies ◽  
Pharmacologic Treatment

scholarly journals Risk of Type 2 Diabetes Mellitus following Gestational Diabetes Pregnancy in Women with Polycystic Ovary Syndrome

2017 ◽  
Vol 2017 ◽  
pp. 1-5 ◽  
Author(s):  
Joan C. Lo ◽  
Jingrong Yang ◽  
Erica P. Gunderson ◽  
Mohammad K. Hararah ◽  
Joel R. Gonzalez ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Gestational Diabetes ◽  
Polycystic Ovary Syndrome ◽  
Polycystic Ovary ◽  
Pharmacologic Treatment ◽  
Ovary Syndrome ◽  
Prepregnancy Obesity

Background. This study examines gestational diabetes mellitus (GDM) in women with polycystic ovary syndrome (PCOS) and the risk of type 2 diabetes mellitus (DM) following GDM pregnancy. Methods. A cohort of 988 pregnant women with PCOS who delivered during 2002–2005 was examined to determine the prevalence and predictors of GDM, with follow-up through 2010 among those with GDM to estimate the risk of DM. Results. Of the 988 pregnant women with PCOS, 192 (19%) developed GDM. Multivariable predictors of GDM included older age, Asian race, prepregnancy obesity, family history of DM, preconception metformin use, and multiple gestation. Among women with PCOS and GDM pregnancy, the incidence of DM was 2.8 (95% confidence interval (CI) 1.9–4.2) per 100 person-years and substantially higher for those who received pharmacologic treatment for GDM (6.6 versus 1.5 per 100 person-years, p<0.01). The multivariable adjusted risk of DM was fourfold higher in women who received pharmacologic treatment for GDM (adjusted hazard ratio 4.1, 95% CI 1.8–9.6). The five-year incidence of DM was 13.1% overall and also higher in the pharmacologic treatment subgroup (27.0% versus 7.1%, p<0.01). Conclusions. The strongest predictors of GDM among women with PCOS included Asian race and prepregnancy obesity. Pharmacologic treatment of GDM is associated with fourfold higher risk of subsequent DM.

Pharmacologic Treatment of Type 2 Diabetes

2015 ◽  
Vol 49 (5) ◽  
pp. 540-556 ◽  
Author(s):  
Linda Tran ◽  
Angela Zielinski ◽  
Arpi H. Roach ◽  
Jennifer A. Jende ◽  
Ann Marie Householder ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Pharmacologic Treatment

Twelve‐year trends in pharmacologic treatment of type 2 diabetes among patients with heart failure in the United States

2020 ◽  
Vol 22 (4) ◽  
pp. 705-710
Author(s):  
Ghadeer K. Dawwas ◽  
Charles E. Leonard ◽  
Mahek Garg ◽  
Scott M. Vouri ◽  
Steven M. Smith ◽  
...  
Keyword(s):  
United States ◽  
Heart Failure ◽  
Type 2 Diabetes ◽  
The United States ◽  
Pharmacologic Treatment ◽  
Patients With Heart Failure

Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus

2012 ◽  
Vol 157 (1) ◽  
pp. 76
Author(s):  
Thibault Richard ◽  
Dany Brohee ◽  
Alain Van Meerhaeghe ◽  
Michel Vanhaeverbeek
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Pharmacologic Treatment

Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus

2017 ◽  
Vol 167 (1) ◽  
pp. 75 ◽  
Author(s):  
Michael J. Barry ◽  
Linda L. Humphrey ◽  
Amir Qaseem
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Pharmacologic Treatment
Sign in / Sign up

Export Citation Format

Share Document